WO2012035131A1 - Treatment of abl overexpressing b-cell lymphoma - Google Patents
Treatment of abl overexpressing b-cell lymphoma Download PDFInfo
- Publication number
- WO2012035131A1 WO2012035131A1 PCT/EP2011/066070 EP2011066070W WO2012035131A1 WO 2012035131 A1 WO2012035131 A1 WO 2012035131A1 EP 2011066070 W EP2011066070 W EP 2011066070W WO 2012035131 A1 WO2012035131 A1 WO 2012035131A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- abl
- bcr
- lymphoma
- treatment
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to the use of bcr-abl inhibitors, such as imatinib, dasatinib and nilotinib, in the treatment of ABL overexpressing B-cell lymphoma, in particular mucosa- associated lymphoid tissue (MALT) lymphoma.
- bcr-abl inhibitors such as imatinib, dasatinib and nilotinib
- Mucosa-associated lymphoid tissue (MALT) lymphoma account for 50% of all primary gastric lymphoma.
- MALT lymphoma The development of gastric MALT lymphoma is tightly linked to chronic infection with the human bacterial pathogen Helicobacter pylori; consequently, antibiotic eradication therapy is now the first line treatment for this malignancy.
- lymphomagenesis is initiated by H. py/or/ ' -associated chronic inflammation and the subsequent accumulation of gastric organized lymphoid tissue ("MALT"), from which individual neoplastic clones may grow out and invade the adjacent epithelium, forming the lympho-epithelial lesions that are a hallmark of low grade MALT lymphoma (Sagaert X. et al., Nat Rev Gastroenterol Hepatol 2010, 7(6): 336-346).
- MALT gastric organized lymphoid tissue
- MALT lymphoma tumor immunoglobulins are clonal, somatically hypermutated and polyreactive, i.e. they bind to a variety of unrelated self- and foreign antigens (Craig V.J. et al., Blood 1 15:581-591 (2010)).
- the same panel of antigens that are recognized by MALT lymphoma surface immunoglobulin induce proliferation of explanted tumor cells, supporting the notion that early low grade gastric MALT lymphoma is an antigen-dependent malignancy.
- Low grade gastric MALT lymphoma are infiltrated by large numbers of T-cells, which are polarized to produce Th2 cytokines such as interleukin-4.
- T-cells prevent the proliferation of tumor cells ex vivo and induces tumor regression in a mouse model of gastric MALT lymphoma, implying a synergistic role for T-cell-derived signals and B-cell receptor-mediated antigen recognition during early MALT lymphoma pathogenesis.
- MALT lymphoma are a sub-group of ABL overexpressing B-cell lymphoma.
- Other such lymphoma of the stomach are, for example, diffuse large B cell lymphoma (DLBCL).
- DLBCL diffuse large B cell lymphoma
- MicroRNAs are well-conserved, 18-25 nucleotide long non-coding RNAs with pivotal roles in post-transcriptional gene regulation. miRNA expression patterns correlate with particular cancer types and are predictive of clinical outcome. Over 50% of miRNA genes are located in cancer-associated genomic regions or in fragile sites. Many miRNAs are known to function as tumor suppressors, regulating the expression of oncoproteins such as RAS and c-MYC.
- Bcr-abI fusion protein is an oncogene fusion protein consisting of BCR (breakpoint cluster region) and ABL (ABL1 , Abelson proto-oncogene 1). It is associated with Philadelphia chromosome, a reciprocal translocation between chromosome 22 and 9, and is often found in chronic myeloid leukemia patients, but also connected with acute lymphoblastic leukemia.
- the bcr-abl fusion protein encodes an unregulated cytoplasm-targeted tyrosine kinase that allows the cells to proliferate without regulation by cytokines. Recently efficient bcr-abl inhibitors have been developed. Imatinib, also known as
- Imatinib is a very efficient drug for the treatment of chronic myelogenous leukemia (CML) and
- GIST gastrointestinal stromal tumors
- the invention relates to bcr-abl inhibitors, such as imatinib, dasatinib and nilotinib, for use in the treatment of ABL overexpressing B-cell lymphoma, in particular mucosa-associated lymphoid tissue (MALT) lymphoma, and to compositions further comprising an antibiotic and/or proton-pump inhibitor for such use.
- bcr-abl inhibitors such as imatinib, dasatinib and nilotinib
- bcr-abl inhibitors such as imatinib, dasatinib and nilotinib
- bcr-abl inhibitors for use in the preparation of a medicament for the treatment of ABL overexpressing B-cell lymphoma, in particular mucosa-associated lymphoid tissue (MALT) lymphoma
- MALT mucosa-associated lymphoid tissue
- a bcr-abl inhibitor such as imatinib, dasatinib and nilotinib.
- A LNA (locked nucleic acid) real-time RT-PCR validation of miR-203 expression in human (h) samples of tonsil (T) and MALT lymphoma (MALT-L). miR-203 levels were normalized to U6 snRNA expression.
- C Expression levels of miR-203 in murine (m) MALT lymphoma (MALT-L) and corresponding gastritis (G) samples as determined by LNA RT-PCR.
- the miR-203 promoter is specifically hypermethylated in MALT lymphoma.
- T human tonsil
- G gastritis
- gDLBCL gastric diffuse large B-cell lymphoma
- Black and white circles represent methylated and unmethylated CpG
- 5'-azacytidine (Aza), alone or in combination with 3 mM 4-phenylbutyric acid (Aza + PBA), or left untreated (-).
- Three single clones were sequenced for each treatment and the percentage of methylated CpG dinucleotides is shown. Black and white circles represent methylated and unmethylated CpG, respectively.
- the invention relates to bcr-abl inhibitors, such as imatinib, dasatinib and nilotinib, for use in the treatment of ABL overexpressing B-cell lymphoma, in particular mucosa-associated lymphoid tissue (MALT) lymphoma.
- Mucosa-associated lymphoid tissue (MALT) lymphoma is a well characterized form a B- cell non-Hodgkin lymphoma.
- the stomach is the most commonly affected organ in which MALT lymphoma pathogenesis is clearly associated with Heliobacter pylori gastro- duodenitis (Sagaert X. et al., Nat Rev Gastroenterol Hepatol 2010, 7(6):336-346).
- MALT lymphoma includes both low grade MALT lymphoma and high grade MALT lymphoma, the more aggressive form of MALT lymphoma, also termed gastric diffuse large B-cell lymphoma (gDLBCL).
- MALT lymphoma comprises forms of the disease in any of the organs that can be inflicted, for example in the stomach, lung, thyroid gland, salivary gland and lacrimal gland, and comprises also its splenic and nodal counterparts.
- B-cell lymphoma overexpressing ABL are, for example, nodal or extranodal diffuse large cell B-cell lymphoma (DLBCL), for example diffuse large B-cell lymphoma of the stomach.
- DLBCL diffuse large cell B-cell lymphoma
- Imatinib is 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)- amino]phenyl]benzamide, and is usually applied as the mesylate.
- Dasatinib is N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl- 4-pyrimidinyl]amino]-5-thiazole carboxamide monohydrate.
- Nilotinib is 4-methyl-N-[3-(4-methyl-1 H-imidazol-1-yl)- 5-(trifluoromethyl)phenyl]-3- [(4-pyridin-3-ylpyrimidin-2-yl) amino]benzamide, applied as the hydrochloride hydrate.
- bcr-abl inhibitors considered are, for example, those listed by Valent P., Clinical Medicine Insights: Therapeutics 2010:365-380, in particular SKI-606 (bosutinib),
- INNO-406 (bafetinib), AZD0530 (saracatinib), AP23464, AP23848, CGP76030, PP1 ,
- this expression is also used to designate salts, hydrates or other solvates. Salts are, in particular, pharmaceutically acceptable salts.
- Acid addition salts may comprise more than one acid molecule, depending on the number of basic nitrogen atoms of the free base.
- Such acid additions salts may be formed with organic or inorganic acids, especially with pharmaceutically acceptable acids. Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid.
- Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, oleic acid, glycolic acid, lactic acid, oxalic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, methane- or ethane- sulfonic acid, 2-hydroxyethanes
- salts with alkali or earth alkali cations are considered, e.g. sodium, potassium, calcium or magnesium salts.
- salts with ammonia, or primary, secondary or tertiary amines are considered, for example with ethanolamine, di(2-hydroxyethyl)amine, tri(2-hydroxyethyl)amine or dimethyl-
- 2-hydroxyethyl-amine also quaternary salts, such as tetramethylammonium, or salts with the basic amino acids lysine or arginine.
- the active ingredient is preferably in the form of a pharmaceutical preparation comprising a bcr-abl inhibitor as active ingredient in chemically pure form, and optionally a pharmaceutically acceptable carrier and optionally adjuvants.
- the bcr-abl inhibitor is used in an amount effective against the bacterial infectious disease in humans.
- the dosage of the active ingredient depends upon the age, weight, and individual condition of the human being, the individual pharmacokinetic data, and the mode of administration.
- the daily dose administered of an bcr-abl inhibitor is from 0.01 mg/kg bodyweight to 100 mg/kg bodyweight, preferably from 0.1 mg/kg bodyweight to 50 mg/kg bodyweight, more preferably from 1 mg/kg to 20 mg/kg bodyweight administered as a single dose or as several doses.
- the bcr-abl inhibitor can be used alone or in combinations with other drugs.
- compositions for enteral administration such as nasal, buccal, rectal or, especially, oral administration, and for parenteral administration, such as subcutaneous, intravenous, intrahepatic or intramuscular administration, are especially preferred.
- the pharmaceutical compositions comprise from approximately 1 % to approximately 95% active ingredient, preferably from approximately 20% to approximately 90% active ingredient.
- compositions of the bcr-abl inhibitor may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, viscosity-increasing agents, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known per se, for example by means of conventional dissolving and lyophilizing processes.
- suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, and also binders, such as starches, cellulose derivatives and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, flow conditioners and lubricants, for example stearic acid or salts thereof and/or polyethylene glycol.
- Tablet cores can be provided with suitable, optionally enteric, coatings. Dyes or pigments may be added to the tablets or tablet coatings, for example for identification purposes or to indicate different doses of active ingredient.
- compositions for oral administration also include hard capsules consisting of gelatin, and also soft, sealed capsules consisting of gelatin and a plasticizer, such as glycerol or sorbitol.
- the capsules may contain the active ingredient in the form of granules, or dissolved or suspended in suitable liquid excipients, such as in oils.
- Slow release oral pharmaceutical preparations are also considered, for example preparations containing swellable polymers, in particular compositions comprising the active ingredient, a polymeric binder, and a non-ionic, pharmaceutically acceptable surfactant.
- Polymeric binders considered are, for example, homo- and copolymers of N-vinylpyrrolidone, cellulose esters or ethers, high molecular weight polyalkylene oxides, polyacrylates, vinyl acetate polymers, polyvinyl alcohol and polysaccharides.
- Transdermal/intraperitoneal and intravenous applications are also considered, for example using a transdermal patch, which allows administration over an extended period of time, e.g. from one to twenty days.
- the bcr-abl inhibitor can be administered alone or in combination with one or more other therapeutic agents, possible combination therapy taking the form of fixed combinations of the bcr-abl inhibitor and one or more other therapeutic agents known in the treatment of MALT lymphoma in humans, the administration being staggered or given independently of one another, or being in the form of a fixed combination.
- antibiotics particularly those known to eradicate H. pylori, for example beta-lactams such as amoxicillin, macrolides such as clarithromycin, chinolones such as levofloxacin, metronidazole, furthermore proton pump inhibitors, such as omeprazole, pantoprazole or rabeprazole.
- beta-lactams such as amoxicillin
- macrolides such as clarithromycin
- chinolones such as levofloxacin
- metronidazole metronidazole
- proton pump inhibitors such as omeprazole, pantoprazole or rabeprazole.
- the invention further relates to bcr-abl inhibitors, such as imatinib, dasatinib or nilotinib, for use in the preparation of a medicament for the treatment of ABL overexpressing B-cell lymphoma, in particular mucosa-associated lymphoid tissue (MALT) lymphoma.
- bcr-abl inhibitors such as imatinib, dasatinib or nilotinib
- the invention further relates to a method of treatment of ABL overexpressing B-cell lymphoma, in particular mucosa-associated lymphoid tissue (MALT) lymphoma comprising administering to a patient in need thereof a therapeutically effective amount of a bcr-abl inhibitor, such as imatinib, dasatinib or nilotinib.
- a bcr-abl inhibitor such as imatinib, dasatinib or nilotinib.
- miR-203 is down-regulated in gastric MALT lymphoma due to promoter hypermethylation.
- the ectopic re-expression of miR-203 in a lymphoma cell line or in primary MALT lymphoma cells down-regulates the expression of the miR-203 target ABL1 and blocks tumor cell proliferation in vitro.
- ABL1 tyrosine kinase activity by imatinib blocks MALT lymphoma cell proliferation ex vivo and prevents tumor formation in mice, suggesting for the first time an important oncogenic role for ABL1 in the
- mice Female BALB/c mice were infected orally at six weeks of age with three consecutive doses of -5x10 7 H. felis (CS1 , ATCC 49179) and maintained in a University of Zurich SPF facility.
- imatinib treatment at the 15 month infection time point mice received 1.2 mM imatinib (-75 mg/kg per day) through their drinking water for 3 months.
- imatinib treatment at the 15 month infection time point mice received 1.2 mM imatinib (-75 mg/kg per day) through their drinking water for 3 months.
- macroscopically visible tumors were collected and single cell suspensions were generated and cultured in RPMI supplemented with 10% FCS and antibiotics.
- Tumor cells were stimulated with 10 ⁇ g/ml Helicobacter lysate and cultured either in the presence or absence of imatinib (Novartis, Basel, Switzerland) or dasatinib (Bristol-Myers Squibb) for 3 days. Tumor cell proliferation was quantified by [ 3 H]-thymidine incorporation assay.
- the Burkitt's lymphoma BL2 cell line was described in Cohen J.H. et al., J Natl Cancer Inst 1987, 78:235.-242.
- BL2 cells were seeded at 5x10 5 cells/ml 24 hours prior to treatment with 5 ⁇ 5'-azacytidine and/or 3 mM 4-phenylbutyric acid (both from Sigma-Aldrich).
- 1x10 6 BL2 cells were nucleoporated using an Amaxa Nucleoporator (Gaithersburg, MD) with either 50 nM or 100 nM of precursor oligonucleotides (either miR-203 specific miRNA precursor or negative control precursor 1 , Ambion, Austin, TX) in a total volume of 2 ml.
- ABL1 expression was analyzed by real time RT-PCR (LightCycler 480 SYBR Green I master kit; Roche, Basel, Switzerland) or Western Blot, using antibodies against ABL1 (BD Biosciences, CA, USA) and a-tubulin (Sigma-Aldrich, St. Louis, MO).
- Primary MALT lymphoma cells were transduced with lentiviral particles harboring a miR-203 expression construct (Systems Biosciences, Mountain View, CA) in the presence of 8 ⁇ g/ml polybrene by spinoculation. Tumor cell proliferation was quantified by a [ 3 H]-thymidine incorporation assay. Expression of mature mir-203 was validated by real-time PCR.
- Microarray-based miRNA expression profiling and bisulfite genomic sequencing miRNA microarray experiments were performed using the Agilent Human miRNA Microarray Kit version 10.0. Normalization and statistical analysis was performed using the quantile normalization implemented in the package PreprocessCore and the package genefilter, respectively. Specific oligonucleotides for methylation-specific PCR (MS-PCR) and bisulfite sequencing of the miR-203 CpG island were performed as described by Bueno M.J. et al., Cancer Cell 2008, 13:496-506.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to bcr-abl inhibitors, such as imatinib, dasatinib or nilotinib, for use in the treatment of ABL overexpressing B-cell lymphoma, in particular mucosa-associated lymphoid tissue (MALT) lymphoma, and to compositions further comprising an antibiotic and/or proton-pump inhibitor for such use. Likewise it relates to bcr-abl inhibitors for use in the preparation of a medicament for the treatment ABL overexpressing B-cell lymphoma, and to a method of treatment of ABL overexpressing B-cell lymphoma comprising administering a bcr-abl inhibitor. These claims are based on the observation that ABL1 plays an important oncogenic role in the pathogenesis of MALT lymphoma.
Description
Treatment of ABL overexpressing B-cell lymphoma
Field of the Invention The invention relates to the use of bcr-abl inhibitors, such as imatinib, dasatinib and nilotinib, in the treatment of ABL overexpressing B-cell lymphoma, in particular mucosa- associated lymphoid tissue (MALT) lymphoma.
Background Art
Mucosa-associated lymphoid tissue (MALT) lymphoma account for 50% of all primary gastric lymphoma. The development of gastric MALT lymphoma is tightly linked to chronic infection with the human bacterial pathogen Helicobacter pylori; consequently, antibiotic eradication therapy is now the first line treatment for this malignancy. MALT
lymphomagenesis is initiated by H. py/or/'-associated chronic inflammation and the subsequent accumulation of gastric organized lymphoid tissue ("MALT"), from which individual neoplastic clones may grow out and invade the adjacent epithelium, forming the lympho-epithelial lesions that are a hallmark of low grade MALT lymphoma (Sagaert X. et al., Nat Rev Gastroenterol Hepatol 2010, 7(6): 336-346).
It has recently been shown that MALT lymphoma tumor immunoglobulins are clonal, somatically hypermutated and polyreactive, i.e. they bind to a variety of unrelated self- and foreign antigens (Craig V.J. et al., Blood 1 15:581-591 (2010)). The same panel of antigens that are recognized by MALT lymphoma surface immunoglobulin induce proliferation of explanted tumor cells, supporting the notion that early low grade gastric MALT lymphoma is an antigen-dependent malignancy. Low grade gastric MALT lymphoma are infiltrated by large numbers of T-cells, which are polarized to produce Th2 cytokines such as interleukin-4. The depletion of T-cells prevents the proliferation of tumor cells ex vivo and induces tumor regression in a mouse model of gastric MALT lymphoma, implying a synergistic role for T-cell-derived signals and B-cell receptor-mediated antigen recognition during early MALT lymphoma pathogenesis.
MALT lymphoma are a sub-group of ABL overexpressing B-cell lymphoma. Other such lymphoma of the stomach are, for example, diffuse large B cell lymphoma (DLBCL).
MicroRNAs are well-conserved, 18-25 nucleotide long non-coding RNAs with pivotal roles in post-transcriptional gene regulation. miRNA expression patterns correlate with particular cancer types and are predictive of clinical outcome. Over 50% of miRNA genes are located in cancer-associated genomic regions or in fragile sites. Many miRNAs are known to function as tumor suppressors, regulating the expression of oncoproteins such as RAS and c-MYC.
Bcr-abI fusion protein is an oncogene fusion protein consisting of BCR (breakpoint cluster region) and ABL (ABL1 , Abelson proto-oncogene 1). It is associated with Philadelphia chromosome, a reciprocal translocation between chromosome 22 and 9, and is often found in chronic myeloid leukemia patients, but also connected with acute lymphoblastic leukemia. The bcr-abl fusion protein encodes an unregulated cytoplasm-targeted tyrosine kinase that allows the cells to proliferate without regulation by cytokines. Recently efficient bcr-abl inhibitors have been developed. Imatinib, also known as
GleevecO/Glivec® (Novartis), dasatinib (Sprycel®, Bristol-Myers Squibb) and nilotinib (Tasigna®, Novartis). Further bcr-abl inhibitors are in development. Imatinib is a very efficient drug for the treatment of chronic myelogenous leukemia (CML) and
gastrointestinal stromal tumors (GIST). The other approved bcr-abl inhibitors are of use, if imatinib resistance is observed, and have a different side effect profile.
Summary of the Invention
The invention relates to bcr-abl inhibitors, such as imatinib, dasatinib and nilotinib, for use in the treatment of ABL overexpressing B-cell lymphoma, in particular mucosa-associated lymphoid tissue (MALT) lymphoma, and to compositions further comprising an antibiotic and/or proton-pump inhibitor for such use. Likewise it relates to bcr-abl inhibitors, such as imatinib, dasatinib and nilotinib, for use in the preparation of a medicament for the treatment of ABL overexpressing B-cell lymphoma, in particular mucosa-associated lymphoid tissue (MALT) lymphoma, and for a method of treatment of ABL overexpressing B-cell lymphoma, in particular mucosa-associated lymphoid tissue (MALT) lymphoma, comprising administering a bcr-abl inhibitor, such as imatinib, dasatinib and nilotinib.
Brief Description of the Figures
Figure 1. miR-203 and its target ABL1 are dysregulated in MALT lymphoma.
(A) LNA (locked nucleic acid) real-time RT-PCR validation of miR-203 expression in human (h) samples of tonsil (T) and MALT lymphoma (MALT-L). miR-203 levels were normalized to U6 snRNA expression.
(B) Expression levels of miR-203 in human gastritis (G) and MALT lymphoma (MALT-L) FFPE tissue samples as determined by LNA RT-PCR.
(C) Expression levels of miR-203 in murine (m) MALT lymphoma (MALT-L) and corresponding gastritis (G) samples as determined by LNA RT-PCR.
(D) ABL1 expression in MALT-L and corresponding gastritis material derived from eight patients. ABL1 transcript levels were quantified by real-time RT-PCR and normalized to GAPDH expression.
(E) miR-203 and ABL1 expression in four pairs of murine MALT lymphoma and corresponding gastritis from the same stomach.
Figure 2. The miR-203 promoter is specifically hypermethylated in MALT lymphoma. Bisulfite sequencing of the miR-203 promoter region in human tonsil (T), gastritis (G), MALT lymphoma (MALT-L), and gastric diffuse large B-cell lymphoma (gDLBCL, i.e. high grade MALT lymphoma) samples. Three representative samples are shown for each tissue type (four for MALT-L), and three single clones are represented for each individual sample. Black and white circles represent methylated and unmethylated CpG
dinucleotides, respectively. All 61 sequenced CpGs are indicated. Figure 3. The expression of miR-203 is regulated epigenetically and controls ABL1 expression and lymphoma cell proliferation.
(A) The DNA methylation status of the miR-203 promoter region in BL2 cells as determined by bisulfite genomic sequencing. Cells were either treated with 5 μΜ
5'-azacytidine (Aza), alone or in combination with 3 mM 4-phenylbutyric acid (Aza + PBA), or left untreated (-). Three single clones were sequenced for each treatment and the percentage of methylated CpG dinucleotides is shown. Black and white circles represent methylated and unmethylated CpG, respectively.
(B, C) Real-time RT-PCR analysis of miR-203 and ABL1 transcript levels (normalized) in BL2 cells with and without drug treatment.
(D) ABL1 protein levels of the experiment outlined in A-C as assessed by Western blot analysis with a-tubulin (aT) serving as a loading control.
(E) Normalized ABL1 expression of BL2 cells transfected with either miR-203 precursor molecules (miR-203) or negative control precursor molecules (C) at 50 nM or 100 nM final concentration.
(F) ABL1 protein levels of the experiment described for E as assessed by Western blot analysis with a-tubulin (aT) serving as loading control.
(G) The proliferation of cells transfected as described for E as determined by
[3H]-thymidine incorporation.
Figure 4. miR-203 re-expression and pharmacological ABL inhibition block MALT lymphoma growth in vitro and in vivo.
(A-C) Primary murine MALT lymphoma cells were transduced with lentiviruses carrying a miR-203-expressing or empty vector. miR-203 and ABL1 expression was assessed by real time RT-PCR; the proliferation of transduced cells was determined by [3H]-thymidine incorporation with (dark grey) or without (light gray) stimulation with H. felis sonicate. C = control (vector alone).
(D, E) [3H]-thymidine incorporation of gastric (D) and advanced splenic (E) primary murine MALT lymphoma cells stimulated with H. felis sonicate and treated with increasing concentrations of imatinib (grey) or dasatinib (white). Unstimulated cells (black) are included for comparison. Vertical bars indicate standard deviations.
(F) Gastric MALT lymphoma formation in female BALB/c mice infected for 18 months with H. felis. One group received imatinib (I) through the drinking water for months 16-18 of the experiment. Macroscopically visible tumors >1 mm in diameter are plotted. C = control, n = number of tumors per mice.
(G) Representative micrographs of H&E-stained (hematoxylin and eosin stained) sections of the mice shown in F. Scale bar indicates 50 μηι.
(H) H. felis colonization as determined by f/aS-specific qPCR of the mice shown in F. m = H. felis copies per stomach.
Detailed Description of the Invention
The invention relates to bcr-abl inhibitors, such as imatinib, dasatinib and nilotinib, for use in the treatment of ABL overexpressing B-cell lymphoma, in particular mucosa-associated lymphoid tissue (MALT) lymphoma. Mucosa-associated lymphoid tissue (MALT) lymphoma is a well characterized form a B- cell non-Hodgkin lymphoma. The stomach is the most commonly affected organ in which
MALT lymphoma pathogenesis is clearly associated with Heliobacter pylori gastro- duodenitis (Sagaert X. et al., Nat Rev Gastroenterol Hepatol 2010, 7(6):336-346). As used herein MALT lymphoma includes both low grade MALT lymphoma and high grade MALT lymphoma, the more aggressive form of MALT lymphoma, also termed gastric diffuse large B-cell lymphoma (gDLBCL). Furthermore, MALT lymphoma comprises forms of the disease in any of the organs that can be inflicted, for example in the stomach, lung, thyroid gland, salivary gland and lacrimal gland, and comprises also its splenic and nodal counterparts. Further B-cell lymphoma overexpressing ABL are, for example, nodal or extranodal diffuse large cell B-cell lymphoma (DLBCL), for example diffuse large B-cell lymphoma of the stomach.
Imatinib is 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)- amino]phenyl]benzamide, and is usually applied as the mesylate.
Dasatinib is N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl- 4-pyrimidinyl]amino]-5-thiazole carboxamide monohydrate. Nilotinib is 4-methyl-N-[3-(4-methyl-1 H-imidazol-1-yl)- 5-(trifluoromethyl)phenyl]-3- [(4-pyridin-3-ylpyrimidin-2-yl) amino]benzamide, applied as the hydrochloride hydrate.
Further bcr-abl inhibitors considered are, for example, those listed by Valent P., Clinical Medicine Insights: Therapeutics 2010:365-380, in particular SKI-606 (bosutinib),
INNO-406 (bafetinib), AZD0530 (saracatinib), AP23464, AP23848, CGP76030, PP1 ,
PD166326, TG100598, TG101 114, ON012380, ON01910, AP24534, VX-680 (tozasertib), VE-465, PHA-739358 (danusertib), KW-2449, AT9283, XL228, AS703569, SGX-70393, DCC-2036, SGX393, and also FTY720 (fingolimod) and BAY 43-9006 (sorafenib). Whenever a "bcr-abl inhibitor" is mentioned, this expression is also used to designate salts, hydrates or other solvates. Salts are, in particular, pharmaceutically acceptable salts. For basic compounds, such as the amines imatinib, nilotinib and other bcr-abl inhibitors with related structures comprising a basic amino function, acid addition salts are primarily considered. Acid addition salts may comprise more than one acid molecule, depending on the number of basic nitrogen atoms of the free base. Such acid additions salts may be formed with organic or inorganic acids, especially with pharmaceutically
acceptable acids. Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid. Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, oleic acid, glycolic acid, lactic acid, oxalic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, methane- or ethane- sulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1 ,2-disulfonic acid, camphor-10- sulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 1 ,5-naphthalene- disulfonic acid, 2-, 3- or 4-methylbenzenesulfonic acid, nicotinic acid, orotic acid, methylsulfuric acid, ethylsulfuric acid, dodecylsulfuric acid, N-cyclohexylsulfamic acid, N- methyl-, N-ethyl- or N-propyl-sulfamic acid, or other organic protonic acids, such as ascorbic acid.
For acid compounds, such as carboxylic acids, salts with alkali or earth alkali cations are considered, e.g. sodium, potassium, calcium or magnesium salts. Alternatively, salts with ammonia, or primary, secondary or tertiary amines are considered, for example with ethanolamine, di(2-hydroxyethyl)amine, tri(2-hydroxyethyl)amine or dimethyl-
2-hydroxyethyl-amine, also quaternary salts, such as tetramethylammonium, or salts with the basic amino acids lysine or arginine.
For the administration, the active ingredient is preferably in the form of a pharmaceutical preparation comprising a bcr-abl inhibitor as active ingredient in chemically pure form, and optionally a pharmaceutically acceptable carrier and optionally adjuvants.
The bcr-abl inhibitor is used in an amount effective against the bacterial infectious disease in humans. The dosage of the active ingredient depends upon the age, weight, and individual condition of the human being, the individual pharmacokinetic data, and the mode of administration. In the case of an individual human having a bodyweight of about 70 kg the daily dose administered of an bcr-abl inhibitor is from 0.01 mg/kg bodyweight to 100 mg/kg bodyweight, preferably from 0.1 mg/kg bodyweight to 50 mg/kg bodyweight, more preferably from 1 mg/kg to 20 mg/kg bodyweight administered as a single dose or as several doses. The bcr-abl inhibitor can be used alone or in combinations with other drugs.
Pharmaceutical compositions for enteral administration, such as nasal, buccal, rectal or, especially, oral administration, and for parenteral administration, such as subcutaneous, intravenous, intrahepatic or intramuscular administration, are especially preferred. The pharmaceutical compositions comprise from approximately 1 % to approximately 95% active ingredient, preferably from approximately 20% to approximately 90% active ingredient.
For parenteral administration preference is given to the use of solutions of the bcr-abl inhibitor, and also suspensions or dispersions, especially isotonic aqueous solutions, dispersions or suspensions which, for example, can be made up shortly before use. The pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, viscosity-increasing agents, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known per se, for example by means of conventional dissolving and lyophilizing processes.
For oral pharmaceutical preparations suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, and also binders, such as starches, cellulose derivatives and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, flow conditioners and lubricants, for example stearic acid or salts thereof and/or polyethylene glycol. Tablet cores can be provided with suitable, optionally enteric, coatings. Dyes or pigments may be added to the tablets or tablet coatings, for example for identification purposes or to indicate different doses of active ingredient. Pharmaceutical compositions for oral administration also include hard capsules consisting of gelatin, and also soft, sealed capsules consisting of gelatin and a plasticizer, such as glycerol or sorbitol. The capsules may contain the active ingredient in the form of granules, or dissolved or suspended in suitable liquid excipients, such as in oils.
Slow release oral pharmaceutical preparations are also considered, for example preparations containing swellable polymers, in particular compositions comprising the active ingredient, a polymeric binder, and a non-ionic, pharmaceutically acceptable surfactant. Polymeric binders considered are, for example, homo- and copolymers of N-vinylpyrrolidone, cellulose esters or ethers, high molecular weight polyalkylene oxides, polyacrylates, vinyl acetate polymers, polyvinyl alcohol and polysaccharides.
Transdermal/intraperitoneal and intravenous applications are also considered, for example using a transdermal patch, which allows administration over an extended period of time, e.g. from one to twenty days.
The bcr-abl inhibitor can be administered alone or in combination with one or more other therapeutic agents, possible combination therapy taking the form of fixed combinations of the bcr-abl inhibitor and one or more other therapeutic agents known in the treatment of MALT lymphoma in humans, the administration being staggered or given independently of one another, or being in the form of a fixed combination.
Possible combination partners considered are antibiotics, particularly those known to eradicate H. pylori, for example beta-lactams such as amoxicillin, macrolides such as clarithromycin, chinolones such as levofloxacin, metronidazole, furthermore proton pump inhibitors, such as omeprazole, pantoprazole or rabeprazole.
The invention further relates to bcr-abl inhibitors, such as imatinib, dasatinib or nilotinib, for use in the preparation of a medicament for the treatment of ABL overexpressing B-cell lymphoma, in particular mucosa-associated lymphoid tissue (MALT) lymphoma.
Pharmaceutical preparations considered are mentioned above. These medicaments are manufactured by methods known in the art, especially by conventional mixing, coating, granulating, dissolving or lyophilizing. The invention further relates to a method of treatment of ABL overexpressing B-cell lymphoma, in particular mucosa-associated lymphoid tissue (MALT) lymphoma comprising administering to a patient in need thereof a therapeutically effective amount of a bcr-abl inhibitor, such as imatinib, dasatinib or nilotinib. The scientific rationale for the use of a bcr-abl inhibitor in the treatment of ABL
overexpressing B-cell is as follows: miR-203 is down-regulated in gastric MALT lymphoma due to promoter hypermethylation. The ectopic re-expression of miR-203 in a lymphoma cell line or in primary MALT lymphoma cells down-regulates the expression of the miR-203 target ABL1 and blocks tumor cell proliferation in vitro. Finally, inhibition of ABL1 tyrosine kinase activity by
imatinib blocks MALT lymphoma cell proliferation ex vivo and prevents tumor formation in mice, suggesting for the first time an important oncogenic role for ABL1 in the
pathogenesis of B-cell tumors not harboring the BCR-ABL1 fusion. Patient material
Human patient material was obtained from eight patients with H. py/or/'-positive, t(77; 78)(q21 :q21)-negative gastric low grade MALT lymphoma that were part of a previously published study conducted at Philipps-University Hospital Marburg, Germany (Huynh M.Q. et al., Leuk Lymphoma 2008, 49:974-983). miRNA expression analysis was performed on archived cases of H. py/or/'-positive gastritis, H. py/or/'-positive gastric low grade MALT lymphoma and gastric high grade lymphoma drawn from the surgical pathology files of the Institute of Pathology at the Cantonal Hospital St. Gallen,
Switzerland. All data were blinded to guarantee patients' protection. All procedures were in agreement with the guidelines for use of human material in research issued by the participating Institutions' Ethics Committees.
Animal experimentation, cell culture, nucleoporation and lentivirus infection
Female BALB/c mice were infected orally at six weeks of age with three consecutive doses of -5x107 H. felis (CS1 , ATCC 49179) and maintained in a University of Zurich SPF facility. For the purpose of imatinib treatment, at the 15 month infection time point mice received 1.2 mM imatinib (-75 mg/kg per day) through their drinking water for 3 months. At the 18 month infection time point, macroscopically visible tumors were collected and single cell suspensions were generated and cultured in RPMI supplemented with 10% FCS and antibiotics. Tumor cells were stimulated with 10 μg/ml Helicobacter lysate and cultured either in the presence or absence of imatinib (Novartis, Basel, Switzerland) or dasatinib (Bristol-Myers Squibb) for 3 days. Tumor cell proliferation was quantified by [3H]-thymidine incorporation assay. The Burkitt's lymphoma BL2 cell line was described in Cohen J.H. et al., J Natl Cancer Inst 1987, 78:235.-242. For demethylation treatment, BL2 cells were seeded at 5x105 cells/ml 24 hours prior to treatment with 5 μΜ 5'-azacytidine and/or 3 mM 4-phenylbutyric acid (both from Sigma-Aldrich). For the purpose of miR-203 re-expression, 1x106 BL2 cells were nucleoporated using an Amaxa Nucleoporator (Gaithersburg, MD) with either 50 nM or 100 nM of precursor oligonucleotides (either miR-203 specific miRNA precursor or negative control precursor 1 , Ambion, Austin, TX) in a total volume of 2 ml. 48 hours after electroporation, the cells were collected and ABL1 expression was analyzed by real time RT-PCR (LightCycler 480 SYBR Green I master kit; Roche, Basel, Switzerland) or Western Blot, using antibodies against ABL1 (BD
Biosciences, CA, USA) and a-tubulin (Sigma-Aldrich, St. Louis, MO). Primary MALT lymphoma cells were transduced with lentiviral particles harboring a miR-203 expression construct (Systems Biosciences, Mountain View, CA) in the presence of 8 μg/ml polybrene by spinoculation. Tumor cell proliferation was quantified by a [3H]-thymidine incorporation assay. Expression of mature mir-203 was validated by real-time PCR.
Microarray-based miRNA expression profiling and bisulfite genomic sequencing miRNA microarray experiments were performed using the Agilent Human miRNA Microarray Kit version 10.0. Normalization and statistical analysis was performed using the quantile normalization implemented in the package PreprocessCore and the package genefilter, respectively. Specific oligonucleotides for methylation-specific PCR (MS-PCR) and bisulfite sequencing of the miR-203 CpG island were performed as described by Bueno M.J. et al., Cancer Cell 2008, 13:496-506.
Claims
1. A bcr-abl inhibitor for use in the treatment of ABL overexpressing B-cell lymphoma.
2. A bcr-abl inhibitor for use in the treatment of mucosa-associated lymphoid tissue (MALT) lymphoma according to claim 1.
3. A bcr-abl inhibitor according to claim 1 or 2 selected from the group consisting of imatinib, dasatinib, nilotinib, SKI-606 (bosutinib), INNO-406 (bafetinib), AZD0530
(saracatinib), AP23464, AP23848, CGP76030, PP1 , PD166326, TG100598, TG101 114, ON012380, ON01910, AP24534, VX-680 (tozasertib), VE-465, PHA-739358 (danusertib), KW-2449, AT9283, XL228, AS703569, SGX-70393, DCC-2036, SGX393, FTY720 (fingolimod), and BAY 43-9006 (sorafenib).
4. A bcr-abl inhibitor according to claim 1 or 2 selected from the group consisting of imatinib, dasatinib, nilotinib, SKI-606 (bosutinib), INNO-406 (bafetinib), AZD0530
(saracatinib), AP23464, AP23848, CGP76030, PP1 , PD166326, TG100598, TG101 114, ON012380, ON01910, AP24534, VX-680 (tozasertib), VE-465, PHA-739358 (danusertib), KW-2449, AT9283, XL228, AS703569, SGX-70393, DCC-2036, and SGX393.
5. A bcr-abl inhibitor according to claim 1 or 2 selected from the group consisting of imatinib, dasatinib, and nilotinib,
6. Imatinib according to claim 1 or 2.
7. Dasatinib according to claim 1 or 2.
8. Nilotinib according to claim 1 or 2.
9. A combination of a bcr-abl inhibitor and an antibiotic and/or a proton-pump inhibitor for use in the treatment of ABL overexpressing B-cell lymphoma.
10. A combination of a bcr-abl inhibitor and an antibiotic and/or a proton-pump inhibitor for use in the treatment of mucosa-associated lymphoid tissue (MALT) lymphoma according to claim 9.
1 1. The combination according to claim 9 or 10 wherein the bcr-abl inhibitor is selected from the group consisting of imatinib, dasatinib, and nilotinib,
12. The combination according to anyone of claims claim 9 to 1 1 wherein the antibiotic is selected from the group consisting of beta-lactams, macrolides, chinolones, and metronidazole.
13. The combination according to anyone of claims 9 to 12 wherein the proton pump inhibitor is selected from the group consisting of omeprazole, pantoprazole, and rabeprazole.
14. A bcr-abl inhibitor for use in the preparation of a medicament for the treatment of ABL overexpressing B-cell lymphoma.
15. A method of treatment of ABL overexpressing B-cell lymphoma comprising administering to a patient in need thereof a therapeutically effective amount of a bcr-abl inhibitor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10176981 | 2010-09-16 | ||
| EP10176981.8 | 2010-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2012035131A1 true WO2012035131A1 (en) | 2012-03-22 |
Family
ID=43063197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2011/066070 Ceased WO2012035131A1 (en) | 2010-09-16 | 2011-09-16 | Treatment of abl overexpressing b-cell lymphoma |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2012035131A1 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016523850A (en) * | 2013-06-14 | 2016-08-12 | インスティトゥト キミク デ サリア、セツ フンダシオ プリバダＩｎｓｔｉｔｕｔ Ｑｕｉｍｉｃ Ｄｅ Ｓａｒｒｉａ，Ｃｅｔｓ Ｆｕｎｄａｃｉｏ Ｐｒｉｖａｄａ | 4-amino-6- (2,6-dichlorophenyl) -2- (phenylamino) -pyrido [2,3-d] pyrimidin-7 (8H) -one derivatives, their synthesis and use |
| US10966966B2 (en) | 2019-08-12 | 2021-04-06 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| GB2592680A (en) * | 2020-03-06 | 2021-09-08 | Zentiva Ks | Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof |
| US11185535B2 (en) | 2019-12-30 | 2021-11-30 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
| US11266635B2 (en) | 2019-08-12 | 2022-03-08 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US11395818B2 (en) | 2019-12-30 | 2022-07-26 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US11986463B2 (en) | 2018-01-31 | 2024-05-21 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of gastrointestinal stromal tumor |
| US12102620B2 (en) | 2018-01-31 | 2024-10-01 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2036893A1 (en) * | 2006-06-30 | 2009-03-18 | Kyowa Hakko Kirin Co., Ltd. | Abl KINASE INHIBITOR |
| WO2009158026A1 (en) * | 2008-06-27 | 2009-12-30 | Synta Pharmaceuticals Corp. | Hydrazonamide compounds that modulate hsp90 activity |
-
2011
- 2011-09-16 WO PCT/EP2011/066070 patent/WO2012035131A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2036893A1 (en) * | 2006-06-30 | 2009-03-18 | Kyowa Hakko Kirin Co., Ltd. | Abl KINASE INHIBITOR |
| WO2009158026A1 (en) * | 2008-06-27 | 2009-12-30 | Synta Pharmaceuticals Corp. | Hydrazonamide compounds that modulate hsp90 activity |
Non-Patent Citations (10)
| Title |
|---|
| BERTONI FRANCESCO ET AL: "In vitro activity of SYK and BCR-ABL inhibitors in aggressive lymphomas.", vol. 108, no. 11, 16 November 2006 (2006-11-16), XP002614078, ISSN: 0006-4971, Retrieved from the Internet <URL:http://abstracts.hematologylibrary.org/cgi/content/abstract/108/11/2520?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=vitro+syk+aggressive&searchid=1&FIRSTINDEX=0&volume=108&issue=11&resourcetype=HWCIT> [retrieved on 20101126] * |
| BOMPAS EMMANUELLE ET AL: "Combination treatment of rituximab and imatinib mesylate for simultaneous relapse of MALT lymphoma and a gastrointestinal stromal tumor.", LEUKEMIA & LYMPHOMA, vol. 45, no. 11, November 2004 (2004-11-01), pages 2353 - 2354, XP009141749, ISSN: 1042-8194 * |
| BUENO M.J. ET AL., CANCER CELL, vol. 13, 2008, pages 496 - 506 |
| CARLO-STELLA CARMELO ET AL: "Preclinical Rationale for the Use of the Multikinase Inhibitor Sorafenib in the Treatment of Human Lymphomas.", vol. 112, no. 11, 16 November 2008 (2008-11-16), XP002611901, ISSN: 0006-4971, Retrieved from the Internet <URL:http://abstracts.hematologylibrary.org/cgi/content/abstract/112/11/2605?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=preclinical+lymphomas&searchid=1&FIRSTINDEX=0&volume=112&issue=11&resourcetype=HWCIT> [retrieved on 20101126] * |
| COHEN J.H., J NATL CANCER INST, vol. 78, 1987, pages 235,242 |
| CRAIG V.J. ET AL., BLOOD, vol. 115, 2010, pages 581 - 591 |
| GUIDETTI ANNA ET AL: "Preliminary Results of a Phase II Trial with the Multikinase Inhibitor Sorafenib in Heavily Pretreated Patients with Relapsed/Refractory Non-Hodgkin Ly", vol. 114, no. 22, 20 November 2009 (2009-11-20), XP002611900, Retrieved from the Internet <URL:http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/1658?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=preliminary+multikinase+refractory&searchid=1&FIRSTINDEX=0&volume=114&issue=22&resourcetype=HWCIT> [retrieved on 20101126] * |
| HUYNH M.Q. ET AL., LEUK LYMPHOMA, vol. 49, 2008, pages 974 - 983 |
| SAGAERT X. ET AL., NAT REV GASTROENTEROL HEPATOL, vol. 7, no. 6, 2010, pages 336 - 346 |
| ZULLO ANGELO ET AL: "Eradication Therapy for Helicobacter pylori in Patients With Gastric MALT Lymphoma: A Pooled Data Analysis", AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 104, no. 8, August 2009 (2009-08-01), pages 1932 - 1937, XP002611903, ISSN: 0002-9270 * |
Cited By (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016523850A (en) * | 2013-06-14 | 2016-08-12 | インスティトゥト キミク デ サリア、セツ フンダシオ プリバダＩｎｓｔｉｔｕｔ Ｑｕｉｍｉｃ Ｄｅ Ｓａｒｒｉａ，Ｃｅｔｓ Ｆｕｎｄａｃｉｏ Ｐｒｉｖａｄａ | 4-amino-6- (2,6-dichlorophenyl) -2- (phenylamino) -pyrido [2,3-d] pyrimidin-7 (8H) -one derivatives, their synthesis and use |
| US11986463B2 (en) | 2018-01-31 | 2024-05-21 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of gastrointestinal stromal tumor |
| US12102620B2 (en) | 2018-01-31 | 2024-10-01 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
| US12023326B2 (en) | 2019-08-12 | 2024-07-02 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US11266635B2 (en) | 2019-08-12 | 2022-03-08 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US11344536B1 (en) | 2019-08-12 | 2022-05-31 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US12318373B2 (en) | 2019-08-12 | 2025-06-03 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US11426390B2 (en) | 2019-08-12 | 2022-08-30 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US11433056B1 (en) | 2019-08-12 | 2022-09-06 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US11529336B2 (en) | 2019-08-12 | 2022-12-20 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US11534432B2 (en) | 2019-08-12 | 2022-12-27 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US11576904B2 (en) | 2019-08-12 | 2023-02-14 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US12295944B2 (en) | 2019-08-12 | 2025-05-13 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US10966966B2 (en) | 2019-08-12 | 2021-04-06 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US12059411B2 (en) | 2019-08-12 | 2024-08-13 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US12059410B2 (en) | 2019-08-12 | 2024-08-13 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US12023327B2 (en) | 2019-08-12 | 2024-07-02 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US11813251B2 (en) | 2019-08-12 | 2023-11-14 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US12023325B2 (en) | 2019-08-12 | 2024-07-02 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US11969414B2 (en) | 2019-08-12 | 2024-04-30 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US11850240B1 (en) | 2019-12-30 | 2023-12-26 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
| US12023328B2 (en) | 2019-12-30 | 2024-07-02 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
| US11896585B2 (en) | 2019-12-30 | 2024-02-13 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| US11903933B2 (en) | 2019-12-30 | 2024-02-20 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
| US11918564B1 (en) | 2019-12-30 | 2024-03-05 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
| US11969415B1 (en) | 2019-12-30 | 2024-04-30 | Deciphera Pharmaceuticals, Llc | (methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
| US11911370B1 (en) | 2019-12-30 | 2024-02-27 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
| US11185535B2 (en) | 2019-12-30 | 2021-11-30 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
| US11844788B1 (en) | 2019-12-30 | 2023-12-19 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
| US11801237B2 (en) | 2019-12-30 | 2023-10-31 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
| US11395818B2 (en) | 2019-12-30 | 2022-07-26 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| US11850241B1 (en) | 2019-12-30 | 2023-12-26 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
| US11793795B2 (en) | 2019-12-30 | 2023-10-24 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| US12318374B2 (en) | 2019-12-30 | 2025-06-03 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
| US12064422B2 (en) | 2019-12-30 | 2024-08-20 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
| US11612591B2 (en) | 2019-12-30 | 2023-03-28 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| US12213968B2 (en) | 2019-12-30 | 2025-02-04 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
| US12213967B2 (en) | 2019-12-30 | 2025-02-04 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
| US12226406B2 (en) | 2019-12-30 | 2025-02-18 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
| US11576903B2 (en) | 2019-12-30 | 2023-02-14 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
| GB2592680A (en) * | 2020-03-06 | 2021-09-08 | Zentiva Ks | Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012035131A1 (en) | Treatment of abl overexpressing b-cell lymphoma | |
| US11135225B2 (en) | Cancer treatments using combinations of CDK and ERK inhibitors | |
| ES2909910T3 (en) | Cancer treatment using combinations of ERK and RAF inhibitors | |
| US10441587B2 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| AU2014262129B2 (en) | Compounds and methods of treating infections | |
| US20240299388A1 (en) | Erk1/2 and shp2 inhibitors combination therapy | |
| US8703787B2 (en) | Methods of using ALK inhibitors | |
| ES2986019T3 (en) | Cancer treatments using combinations of ERK and MEK type 2 inhibitors | |
| JP2013522236A5 (en) | ||
| AU2014246667A1 (en) | Methods of treating diseases characterized by excessive Wnt signalling | |
| JP2025503385A (en) | Therapeutically targeting gastrointestinal stromal tumors (GISTs) by disrupting the menin-MLL epigenetic complex | |
| WO2020010280A1 (en) | Combination therapy with mek inhibitor and cdk4/6 inhibitor to treat pancreatic cancer | |
| CN107249638A (en) | Apimod for the treatment of kidney cancer | |
| CN110198716A (en) | Treatment of cancer | |
| JP2017502016A (en) | Treatment of cancer using a combination of a type 1 MEK inhibitor and an ERK inhibitor | |
| CN107206090A (en) | Use of apimod in the treatment of colorectal cancer | |
| WO2023035223A1 (en) | Pharmaceutical composition and use thereof | |
| CN105189786B (en) | FALZ as a target for therapy to treat cancer | |
| TWI526211B (en) | RNAi molecules for thymidine nucleotide synthesis enzymes and their use | |
| US20220047573A1 (en) | Methods for treating vascular malformations | |
| TWI891650B (en) | Methods for treating vascular malformations | |
| KR20200138303A (en) | Triple pharmaceutical combination comprising dabrafenib, trametinib and ERK inhibitors | |
| EP3515431A1 (en) | Compositions and methods for treatment of cancer | |
| TWI804455B (en) | Uses of rosoxacin in the inhibition of metastasis of triple-negative breast cancer | |
| CN109715149A (en) | The method for treating oophoroma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11760452 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11760452 Country of ref document: EP Kind code of ref document: A1 |